ID   BHP 2-7
AC   CVCL_6283
SY   BHP2-7; BHP-2
DR   BioSample; SAMN03151970
DR   Cosmic; 1005446
DR   Cosmic; 1094764
DR   Lonza; 783
DR   Wikidata; Q54796499
RX   PubMed=9253346;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
RX   PubMed=25365311;
RX   PubMed=29066502;
RX   PubMed=31443247;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00182.
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:18782; CCDC6 + HGNC; HGNC:9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Omics: Genomics; Mitochondrial genome sequencing.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=21868764; PubMed=25365311
ST   Amelogenin: X
ST   CSF1PO: 8,10 (PubMed=25365311)
ST   CSF1PO: 11,12 (PubMed=21868764)
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 13,16
ST   D21S11: 30,31.2
ST   D3S1358: 16,17
ST   D5S818: 8,10
ST   D7S820: 9,11 (PubMed=25365311)
ST   D7S820: 11 (PubMed=21868764)
ST   FGA: 20,21
ST   TH01: 9 (PubMed=21868764)
ST   TH01: 11 (PubMed=25365311)
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6298 ! TPC-1
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 29
CH   CVCL_4W01 ! BHP2-7 Pazopanib selected
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe, Rebecca E.
RA   Klopper, Joshua Paul
RA   Korch, Christopher T.
RA   Pugazhenthi, Umarani
RA   Benezra, Miriam
RA   Knauf, Jeffrey A.
RA   Fagin, James Alexander
RA   Marlow, Laura A.
RA   Copland, John Alton 3rd
RA   Smallridge, Robert Christian
RA   Haugen, Bryan R.
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver, Willem E.
RA   Demmers, Joris
RA   Oosting, Jan
RA   Sahraeian, Shima
RA   Boot, Arnoud
RA   Ruano, Dina
RA   van Wezel, Tom
RA   Morreau, Hans
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis, Amanda
RA   Theodosopoulos, George
RA   Atkin, Isobel
RA   Drexler, Hans Gunther
RA   Kohara, Arihiro
RA   MacLeod, Roderick A.F.
RA   Masters, John R.W.
RA   Nakamura, Yukio
RA   Reid, Yvonne A.
RA   Reddel, Roger Robert
RA   Freshney, Robert Ian
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao, Mei
RA   Sano, Daisuke
RA   Pickering, Curtis R.
RA   Jasser, Samar A.
RA   Henderson, Ying C.
RA   Clayman, Gary L.
RA   Sturgis, Erich M.
RA   Ow, Thomas J.
RA   Lotan, Reuben
RA   Carey, Thomas E.
RA   Sacks, Peter G.
RA   Grandis, Jennifer Rubin
RA   Sidransky, David
RA   Heldin, Nils-Erik
RA   Myers, Jeffrey N.
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=9253346; DOI=10.1210/jcem.82.8.4136;
RA   Ohta, Kazuyasu
RA   Pang, Xuan-Ping
RA   Berg, Loretta
RA   Hershman, Jerome Marshall
RT   "Growth inhibition of new human thyroid carcinoma cell lines by
RT   activation of adenylate cyclase through the beta-adrenergic
RT   receptor.";
RL   J. Clin. Endocrinol. Metab. 82:2633-2638(1997).
//
RX   PubMed=31443247; DOI=10.3390/cancers11081185; PMCID=PMC6721552;
RA   Aydemirli, Mehtap Derya
RA   Corver, Willem E.
RA   Beuk, Ruben
RA   Roepman, Paul
RA   Solleveld-Westerink, Nienke
RA   van Wezel, Tom
RA   Kapiteijn, Ellen H.W.
RA   Morreau, Hans
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).
//
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896;
RA   Garg, Manoj
RA   Okamoto, Ryoko
RA   Nagata, Yasunobu
RA   Kanojia, Deepika
RA   Venkatesan, Subhashree
RA   Anand, Mayakonda Thippeswamy
RA   Braunstein, Glenn D.
RA   Said, Jonathan William
RA   Doan, Ngan B.
RA   Ho, Quoc
RA   Akagi, Tadayuki
RA   Gery, Sigal
RA   Liu, Li-Zhen
RA   Tan, Kar-Tong
RA   Chang, Wee Joo
RA   Yang, Henry He
RA   Ogawa, Seishi
RA   Koeffler, Harold Phillip
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
//